Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Injection site reaction

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    146 result(s) found for: Injection site reaction. Displaying page 5 of 8.
    « Previous 1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2011-003218-17 Sponsor Protocol Number: TRANEX1 Start Date*: 2012-11-08
    Sponsor Name:Hospital Universitario La Paz
    Full Title: Efficacy of topical tranexamic acid versus intravenous administration to reduce blood transfussion rate in total knee arthroplasty surgery: phase III, unicentric, controlled,double blind, randomiz...
    Medical condition: El sangrado perioperatorio es común en intervenciones quirúrgicas de ortopedia, especialmente en los reemplazos de rodilla con una estimación media de transfusión de concentrados de hematíes de un...
    Disease: Version SOC Term Classification Code Term Level
    15.0 10028395 - Musculoskeletal and connective tissue disorders 10033380 Pain back LLT
    15.0 10038738 - Respiratory, thoracic and mediastinal disorders 10052438 Paranasal sinus discomfort PT
    15.0 10021428 - Immune system disorders 10040562 Shock anaphylactic anaphylactoid LLT
    15.0 10017947 - Gastrointestinal disorders 10047700 Vomiting PT
    15.0 10017947 - Gastrointestinal disorders 10028813 Nausea PT
    15.0 10047065 - Vascular disorders 10066331 Arterial hypotension LLT
    15.0 10015919 - Eye disorders 10047514 Vision central defective LLT
    15.0 10029205 - Nervous system disorders 10051385 Drug-induced headache LLT
    15.0 10047065 - Vascular disorders 10043566 Thromboembolism LLT
    15.0 10015919 - Eye disorders 10047518 Vision disorders HLGT
    15.0 10017947 - Gastrointestinal disorders 10017947 Gastrointestinal disorders SOC
    15.0 10029205 - Nervous system disorders 10027606 Migraine type headaches LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-011737-27 Sponsor Protocol Number: BASALIT Start Date*: 2010-01-07
    Sponsor Name:University Leipzig
    Full Title: A multi centre randomised placebo-controlled double-blind clinical trial for the evaluation of efficacy of specific immunotherapy with an aluminium hydroxide-adsorbed recombinant hypoallergenic der...
    Medical condition: Immediate type allergy to soy proteins in patients with birch pollinosis
    Disease: Version SOC Term Classification Code Term Level
    13.1 10021428 - Immune system disorders 10057630 Protein allergy LLT
    13.1 10021428 - Immune system disorders 10066093 Birch pollen allergy LLT
    13.1 10021428 - Immune system disorders 10016946 Food allergy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003087-40 Sponsor Protocol Number: PHRC-N-2015 Start Date*: 2017-01-17
    Sponsor Name:UHangers
    Full Title: Interest of intraveinous iron and tranexamic acid to reduce transfusion in hip fracture patients - HIFIT Study
    Medical condition: Hip fracture
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-002105-11 Sponsor Protocol Number: BTT-gpASIT009 Start Date*: 2015-11-10
    Sponsor Name:BioTech Tools S.A.
    Full Title: A multicenter, international, randomised, double-blind, placebo controlled study to demonstrate the clinical efficacy and safety of a subcutaneous immunotherapy with gpASIT+™ in patients with grass...
    Medical condition: Treatment of seasonal grass pollen rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004870 10019170 Hay fever LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) CZ (Completed) ES (Completed) FR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001213-12 Sponsor Protocol Number: HGT-FIR-096 Start Date*: 2014-09-05
    Sponsor Name:Shire Orphan Therapies, Inc.
    Full Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study Evaluating the Safety and Efficacy of Icatibant as a Treatment for Angiotensin-Converting Enzyme Inhibitor (ACE...
    Medical condition: ACE-I-induced angioedema
    Disease: Version SOC Term Classification Code Term Level
    17.0 10040785 - Skin and subcutaneous tissue disorders 10002424 Angioedema PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-016636-13 Sponsor Protocol Number: 113173 Start Date*: 2010-06-28
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: An open, dose-escalation Phase I/II study to assess the safety, immunogenicity and clinical activity of recPRAME + AS15 Antigen-Specific Cancer Immunotherapeutic as first-line treatment of patients...
    Medical condition: First-line treatment of patients with PRAME-positive unresectable stage III or IV metastatic melanoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2008-008251-42 Sponsor Protocol Number: 26014 Start Date*: 2009-09-07
    Sponsor Name:Erasmus MC
    Full Title: Clinical and immunological effects of imiquimod and HPV-vaccination compared to imiquimod alone in female patients with Usual type VIN
    Medical condition: In this trial, the efficacy of Gardasil combined with imiquimod in women with usual type Vulvar Intraepithelial Neoplasia is investigated.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047778 Vulvar cancer in situ LLT
    9.1 10066416 Vulvovaginal human papilloma virus infection LLT
    9.1 10046859 Vaccination LLT
    9.1 10062059 Histology abnormal LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-004122-22 Sponsor Protocol Number: APHP220097 Start Date*: 2023-06-02
    Sponsor Name:ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (AP-HP)
    Full Title: Monalizumab and MEDI5752 in patients with MSI and/or dMMR metastatic cancer
    Medical condition: adult patients in all MSI/DMMR solid tumor types
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-019374-32 Sponsor Protocol Number: CP-4-003 Start Date*: 2010-07-15
    Sponsor Name:ModigeneTech Ltd.
    Full Title: A Phase II, Dose and Frequency Finding Study of MOD-4023 in Growth Hormone Deficient Adults (GHDA)
    Medical condition: Growth Hormone Deficiency
    Disease: Version SOC Term Classification Code Term Level
    12.1 10056438 Growth hormone deficiency LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Completed) HU (Completed) SI (Completed) CZ (Completed) DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003660-31 Sponsor Protocol Number: B7841005 Start Date*: 2020-09-07
    Sponsor Name:Pfizer Inc.
    Full Title: An Open-Label Study in Adolescent and Adult Severe (Coagulation Factor Activity <1%) Hemophilia A or B Patients With or Without Inhibitors Comparing Standard Treatment to PF-06741086 Prophylaxis
    Medical condition: Hemophilia A or B
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10060613 Hemophilia A (Factor VIII) LLT
    20.0 100000004850 10060612 Hemophilia A LLT
    20.0 100000004850 10060614 Hemophilia B (Factor IX) LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended) FR (Completed) BG (Completed) GB (GB - no longer in EU/EEA) ES (Restarted) IE (Completed) HR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-017938-46 Sponsor Protocol Number: M11-328 Start Date*: 2010-08-24
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Double-blind, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects with Enthesitis Related Arthritis
    Medical condition: Enthesitis Related Arthritis (ERA)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10003246 Arthritis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) ES (Completed) IE (Completed) SE (Completed) IT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-004336-28 Sponsor Protocol Number: PQBirch203 Start Date*: 2013-08-19
    Sponsor Name:Allergy Therapeutics (UK) Ltd.
    Full Title: A multi-centre, double-blind dose-ranging study to evaluate the efficacy and safety/tolerability of Birch Modified Allergen Tyrosine-adsorbed + MPL (POLLINEX Quattro® Birch) in Subjects with season...
    Medical condition: seasonal allergic rhinoconjunctivitis due to birch pollen
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-005386-67 Sponsor Protocol Number: 20140318 Start Date*: 2017-03-27
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 1b/2, Multicenter, Open-label, Basket Trial to Evaluate the Safety of Talimogene Laherparepvec Injected into Liver Tumors Alone and in Combination With Systemic Pembrolizumab in Phase 1b an...
    Medical condition: Hepatocellular carcinoma (HCC) and metastatic liver tumors (non-HCC)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    21.0 100000004864 10025628 Malignant liver tumour non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) AT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2022-002312-23 Sponsor Protocol Number: LY06006/MRCT-301 Start Date*: 2023-05-25
    Sponsor Name:Shandong Boan Biotechnology Co., Ltd.
    Full Title: A randomized, double-blind, parallel-group, active-controlled comparative study to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of LY06006 compared with EU-Prolia in postmeno...
    Medical condition: Postmenopausal osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10031285 Osteoporosis postmenopausal PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BG (Trial now transitioned) CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-003839-20 Sponsor Protocol Number: CVT5127 Start Date*: 2009-02-24
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Open-Label, Parallel-Group, Exploratory Study to Evaluate the Efficacy and Safety of 400 µg Regadenoson Bolus for Pharmacological Stress Echocardiography
    Medical condition: Suspected coronary artery disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011078 Coronary artery disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004509-30 Sponsor Protocol Number: 012020 Start Date*: 2021-05-13
    Sponsor Name:INSTITUTO DE ESTUDIOS DE CIENCIAS DE LA SALUD DE CASTILLA Y LEON
    Full Title: A prospective structural, diffusion and connectomics MRI study on migraine patients treated with Fremanezumab
    Medical condition: MIGRAINE
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10027603 Migraine headaches HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003838-32 Sponsor Protocol Number: ADC01 Start Date*: 2019-01-11
    Sponsor Name:Sanofi Pasteur
    Full Title: Safety and Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed (SP0173) in Healthy Adolescents, Adults, and Older Adults
    Medical condition: Tetanus Diphtheria Pertussis
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-001778-17 Sponsor Protocol Number: 201190 Start Date*: 2016-03-17
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIb, open-label, multi-country, multi-centre, long-term follow-up study (ZOE-LTFU) of studies 110390 and 113077 (ZOSTER-006/022) to assess the prophylactic efficacy, safety, and immunogeni...
    Medical condition: Vaccination against HZ and its related complications in adults older than 50 years (at the time of primary vaccination).
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004862 10019982 Herpes zoster NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) EE (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) DE (Completed) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-012280-34 Sponsor Protocol Number: 26866138-LYM-2034 Start Date*: 2009-12-04
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Randomized, Open-Label, Multicenter, Phase 2 Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) or Rituximab, Cyclophosphamide, Doxorubicin, ...
    Medical condition: Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) PT (Completed) CZ (Completed) DE (Completed) FR (Completed) ES (Completed) IT (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2007-005669-37 Sponsor Protocol Number: 26866138-LYM-3002;Phase3 Start Date*: 2008-04-29
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Randomised, Open-Label, Multicentre Phase 3 Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone (VcR-CAP) or Rituximab, Cyclophosphamide, Doxorubicin, ...
    Medical condition: Patients with newly diagnosed Mantle Cell Lymphoma who are not eligible for bone marrow transplant. To determine which regimen of chemotherapy (VcR-CAP or R-CHOP) provides greater benefit in new...
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061275 Mantle cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) PT (Completed) CZ (Completed) AT (Completed) IT (Completed) HU (Completed) DE (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 17:47:11 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA